InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 23 February 2024

PRIMROSE: This study is assessing a new targeted therapy (called AZD3470) in people with advanced or metastatic solid cancers that are MTAP deficientA Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours That Are MTAP Deficient

Clinical summary

Summary

This study consists of several modules, evaluating the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of AZD3470, a targeted therapy, when given alone (as monotherapy) or in combination with other anti-cancer agents.

Module 1 will include a dose escalation and DDI (Part A) and dose optimisation and expansion (Part B). New modules for combination treatments may be added in the future based on emerging data from Module 1.

What is AZD3470?

AZD3470 is a novel, potent and selective, second-generation, methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.

Conditions

This trial is treating patients with advanced or metastatic solid cancers that are MTAP deficient

Cancer

Multi-Cancer Multi-Cancer

Age

People18+

Phase

I/II

Trial Acronym

PRIMROSE

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

AstraZeneca

Scientific Title

A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours That Are MTAP Deficient

Eligibility

Inclusion

  • Participant must be at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the ICF.
  • Willing to provide archival and/or baseline tumour sample to meet the minimum tissue requirement for central MTAP deficiency testing.
  • Participants must have received and progressed, are refractory or are intolerant to standard therapy for the specific tumour type. All participants are required to have had at least one prior line of treatment in the recurrent or metastatic setting.
  • MTAP deficient tumours defined as evidence of homozygous deletion of one or more exons of the MTAP gene in tumour tissue AND/OR loss of MTAP expression in the tumour tissue.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • A minimum life expectance of 12 weeks in the opinion of the Investigator.
  • Participants must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
  • Adequate organ and bone marrow reserve function.
  • Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion

  • Spinal cord compression or symptomatic and unstable brain metastases or leptomeningeal disease.
  • Allogenic organ transplantation.
  • Any significant laboratory finding or any severe and uncontrolled medical condition.
  • Any of the following cardiac criteria:
  • LVEF ≤ 50%
  • prior or current cardiomyopathy
  • clinically active cardiovascular disease, or a history of myocardial infarction within the last 6 months
  • uncontrolled angina or acute coronary syndrome within 6 months
  • severe valvular heart disease
  • uncontrolled hypertension
  • risk of brain perfusion problems. Stroke or transient ischemic attack in the last 6 months, undergone coronary artery bypass graft, angioplasty or vascular stent
  • chronic heart failure
  • factors that increase the risk of QTc prolongation or risk of arrhythmic events
  • Mean resting QTcF > 470 msec or any clinically important abnormalities in rhythm
  • Use of therapeutic anti-coagulation for treatment of active thromboembolic events.
  • Serologic active hepatitis B or C infection.
  • Known to have tested positive for Human immunodeficiency virus (HIV).
  • Confirmed or suspected ILD/pneumonitis or history of (non-infectious) ILD/pneumonitis that required oral or IV steroids or supplemental oxygen
  • Active gastrointestinal disease or other condition that would interfere with oral therapy.
  • History of another primary malignancy.
  • Unresolved toxicities from prior anti-cancer therapy, except alopecia and neuropathy.
  • Prior treatment with a protein arginine methyltransferase 5 (PRMT5) inhibitor.

Inclusion

  • You have had a certain type of treatment or surgical procedure.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.